2015: Fellow of the Higher Education Academy 2001 - 2004: PhD, University of Cambridge 1997 - 2001: MSci, St Catharine’s College, University of Cambridge 2007-2014: RCUK Academic Fellow in Medicinal Chemistry, University of Bradford 2004-2007: Postdoctoral Research Associate, The University of Manchester

Dual/multi-integrin antagonism ; Synthesis of bioactive natural products ; New synthetic methods

M. J. Stephenson, L. A. Howell, M. A. O'Connell, K. R. Fox, C. Adcock, J. Kingston, H. Sheldrake, K. Pors, S. P. Collingwood, M. Searcey. The solid phase synthesis of duocarmycin analogues and the effect of C-terminal substitution on biological activity. J Org Chem. 2015, 80, 9454-9467 H. M. Sheldrake and L. H. Patterson. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. J. Med. Chem., 2014, 57, 6301-6315 H.M. Sheldrake, S. Travica, I. Johansson, P. Loadman, M. Sutherland, L. Elsalem, N. Illingworth, A. Cresswell, T. Reuillon, Tristan; S. Shnyder, S. Mkrtchian, M. Searcey, M. Sundberg, L. Patterson and K. Pors. Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. J. Med. Chem. 2013, 56, 6273-6277 S. Travica, K. Pors, P. M. Loadman, S. D. Shnyder, I. Johansson, M. N. Alandas, H. M. Sheldrake, S. Mkrtchian, L. H. Patterson, and M. Ingelman-Sundberg. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin. Cancer Res. 2013, 19, 2952-2961 M. Sutherland, P. Loadman, J. H. Gill, J. P. Laye, H. M. Sheldrake, N. Illingworth, M. N. Alandas, P. A. Cooper, M. Searcey, K. Pors, S. D. Shnyder, and L. H. Patterson. Antitumor activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol. Cancer Ther. 2013, 12, 27-37 M. Sutherland, P. Loadman, J. H. Gill, J. P. Laye, H. M. Sheldrake, N. Illingworth, M. N. Alandas, P. A. Cooper, M. Searcey, K. Pors, S. D. Shnyder, and L. H. Patterson. Antitumor activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol. Cancer Ther. 2013, 12, 27-37 M. Sutherland, A. Gordon, S. D. Shnyder, L. H. Patterson and H. M. Sheldrake. RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis. Cancers, 2012, 4, 1106-1145. (Open access: go to http://www.mdpi.com/2072-6694/4/4/1106 to read this review) Pors, K., Loadman, P.M., Shnyder, S.D., Sutherland, M., Sheldrake, H.M., Guino, M., Kiakos, K., Hartley, J.A., Searcey, M., Patterson, L.H. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity, Chem Commun.,2011, 47, 12062-12064 Sheldrake, H.M., Patterson, L.H., "Function and Antagonism of beta 3 integrins in the development of cancer therapy," Curr Cancer Drug Targets, 2009, 9, 519-540 Sheldrake, H.M., Jamieson,C., Pascu, S.I., and Burton, J.W., Synthesis of the originally proposed structure of elatenyne and an enyne from Laurencia majuscula, Org. Biomol. Chem., 2009, 7, 238-252 Pritchard, R.G., Sheldrake, H.M., Taylor, I.Z., and Wallace, T.W., "Rapid stereoselective access to the tetracyle core of puupehenone and related sponge metabolites using metal-free radical cyclisations of cyclohexenyl-substituted 3-bromochroman-4-ones," Tetrahedron Lett, 2008, 49, 4156-4159 Sheldrake, H.M., Wallace, T.W., and Wilson, C.P., "Functionalised Cyclobutenes via Multicomponent Thermal [2+2] Cycloaddition Reactions", Org. Lett., 2005, 7, 4233-4236